Search
                    Arkansas Paid Clinical Trials
A listing of 674  clinical trials  in Arkansas  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            301 - 312 of 674
        
                Arkansas is currently home to 674 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.             
        
        
    Gender:
                ALL
            Ages:
                Between 0 hours and 24 hours
            Trial Updated:
                07/22/2025
            
            Locations: Arkansas Children's Hospital, Little Rock, Arkansas  +1 locations         
        
        
            Conditions: Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
        
            
        
    
                
                                    A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
                                
            
            
        Recruiting
                            
            
                TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/22/2025
            
            Locations: University of Arkansas, Little Rock, Arkansas         
        
        
            Conditions: Hepatocellular Cancer
        
            
        
    
                
                                    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
                                
            
            
        Recruiting
                            
            
                This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                07/22/2025
            
            Locations: Arkansas Children's Hospital, Little Rock, Arkansas  +1 locations         
        
        
            Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
        
            
        
    
                
                                    Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
                                
            
            
        Recruiting
                            
            
                BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/21/2025
            
            Locations: Highlands Oncology Group, Springdale, Arkansas         
        
        
            Conditions: Advanced Solid Tumor
        
            
        
    
                
                                    Study of ALTO-300 in MDD
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                07/21/2025
            
            Locations: Site 193, Rogers, Arkansas         
        
        
            Conditions: Major Depressive Disorder
        
            
        
    
                
                                    A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
                                
            
            
        Recruiting
                            
            
                This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing             
        
        
    Gender:
                ALL
            Ages:
                Between 6 months and 72 months
            Trial Updated:
                07/21/2025
            
            Locations: Arkansas Children's Hospital Research Institute, Little Rock, Arkansas         
        
        
            Conditions: Recurrent Wheezing, Wheezing Lower Respiratory Illness
        
            
        
    
                
                                    A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
                                
            
            
        Recruiting
                            
            
                This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                07/21/2025
            
            Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas         
        
        
            Conditions: Endometrial Adenocarcinoma
        
            
        
    
                
                                    Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
                                
            
            
        Recruiting
                            
            
                Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.             
        
        
    Gender:
                ALL
            Ages:
                31 years and below
            Trial Updated:
                07/21/2025
            
            Locations: Arkansas Children's Hospital, Little Rock, Arkansas         
        
        
            Conditions: Neuroblastoma
        
            
        
    
                
                                    Transformative Research in Diabetic Nephropathy
                                
            
            
        Recruiting
                            
            
                This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and link them to biomarkers that characterize those patients have a rapid decline in kidney function (\> 5 mL/min/1.73m2/year) from those with lesser degrees of kidney function change over the period of...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 100 years
            Trial Updated:
                07/21/2025
            
            Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas         
        
        
            Conditions: Diabetic Nephropathies, Diabetic Glomerulosclerosis
        
            
        
    
                
                                    A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
                                
            
            
        Recruiting
                            
            
                The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD).
For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.             
        
        
    Gender:
                ALL
            Ages:
                Between 21 years and 65 years
            Trial Updated:
                07/18/2025
            
            Locations: Woodland International Research Group, Little Rock, Arkansas         
        
        
            Conditions: Alcohol Use Disorder
        
            
        
    
                
                                    A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
                                
            
            
        Recruiting
                            
            
                The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                07/18/2025
            
            Locations: Preferred Research Partners Inc., Little Rock, Arkansas         
        
        
            Conditions: Obstructive Sleep Apnea, Hypertension
        
            
        
    
                
                                    Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
                                
            
            
        Recruiting
                            
            
                Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/18/2025
            
            Locations: Clinical Site 3, North Little Rock, Arkansas         
        
        
            Conditions: Atopic Dermatitis
        
            
        
    